Equillium Inc · Q2 2022 earnings

Briefing

Equillium reported financial results for the second quarter of 2022 and provided an update on its clinical development programs.

Equillium's second quarter focused on executing development programs with itolizumab and advancing clinical development of EQ101 and EQ102. The company is preparing to initiate a Phase 2 clinical study of EQ101 in alopecia areata and a Phase 1 SAD/MAD study of EQ102, both expected to commence in the second half of the year. Enrollment continues for the Phase 3 EQUATOR study in acute graft-versus-host disease, with interim data pending from the Phase 1b EQUALISE study of itolizumab in patients with lupus nephritis.

• Presented data demonstrating itolizumab’s impact on effector T cell function in acute graft-versus-host disease (aGVHD) and treatment associated with high rates of overall clinical response in the treatment of aGVHD.
• Announced data confirming CD6 as a target to prevent pathogenic T cell recruitment into inflamed organs and that itolizumab-induced reduction of CD6 from T effector cells promotes the development and activity of T regulatory cells.
• Introduced data from the company’s multi-cytokine inhibitor technology and platform focusing on the design and development of multi-specific cytokine inhibitors, and the importance of targeting biological synergy to optimize therapeutic outcomes.
• Preparing to initiate a Phase 2 clinical study of EQ101 in alopecia areata and a Phase 1 SAD/MAD study of EQ102 – both of which are on track to commence during the second half of this year.

Headline financials

Revenue & EPS history

Equillium anticipates several milestones and catalysts, including interim data from the EQUALISE Phase 1b study in lupus nephritis, initiation of a Phase 2 study of EQ101 in alopecia areata, and initiation of a Phase 1 study of EQ102 in normal healthy volunteers and celiac disease patients, all expected in the second half of 2022.